The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-22 and is reviewed periodically as new material appears.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Evidence from the study of strontium, carbon and oxygen isotopic composition of remains of Notiomastodon platensis from Pleistocene sites in the states of Pernambuco, Paraíba and Sergipe (Brazil), indicative of a predominantly C4-based diet of the studied individuals and indicating that the studied sample included both sedentary and mobile individuals, is presented by Cruz et al. (2026). The first complete skull of a member of the genus Cuvieronius (C. cf. tropicus) from North America reported to date is described from the Pleistocene (Irvingtonian) strata of the Camp Rice Formation (New Mexico, United States) by Houde et al. (2026), who argue that North/Central American and South American members of the genus Cuvieronius likely represent two distinct cryptic species. González-Guarda et al. (2026) reconstruct the environment of late Pleistocene Notiomastodon platensis and Cuvieronius hyodon from Ecuador on the basis of their tooth wear and carbon isotopic composition of their tooth enamel, interpreted as indicative of predominantly open and dry habitats. Kumar (2026) reports the first discovery of fossil material of Anancus sivalensis from Indian Siwaliks, recovered from the Pliocene Tatrot Formation in Himachal Pradesh.
Myomesin-2, also known as M-protein, is a protein that in humans is encoded by the MYOM2 gene. M-protein is expressed in adult cardiac muscle and fast skeletal muscle, and functions to stabilize the three-dimensional arrangement of proteins comprising M-band structures in a sarcomere.
Jaquelyn Patricia Longworth, Operational Safety and Policy Manager, Nuclear Electric Ltd. For services to Engineering Management. Walter Herbert Love. For services to Radio Journalism. Maurice Ernest Lowe, Engineering Manager, Vosper Thornycroft (UK) Ltd. For services to the Defence Industry. William Lowe. For services to the Library Service. June Valerie Lucas. For services to the community in Stanford Rivers, Essex. Brenda Germaine Lynn, Sub Divisional Officer, Special Constabulary, West Yorkshire Police. For services to the Police. Monica Lynskey, lately Administrative Officer, Office for Standards in Education. James Archibald MacDonald, Head Greenkeeper, Royal Lytham & St Annes Golf Club. For services to Golf. Thomas MacDougall, Retained Sub-Officer, Tayside Fire Brigade. For services to the Fire Service. Williamina MacGregor, School Cook, Lochardil Primary School, Inverness. For services to Education. Jean Macinnes. For services to the Citizens' Advice Bureau in Aberdeen. Laurence Macintyre, Chief Superintendent, Strathclyde Police. For services to the Police. John Kenneth MacKay, Crofter. For services to the community in Sutherlandshire. John Watson Mackay, Head of Recreation and Access Branch, Research and Advisory Services, Directorate, Scottish Natural Heritage. For services to Countryside Recreation. Florence King MacKenzie, Director, Scottish Churches Architectural Heritage Trust. For services to the Restoration of Church Buildings. George MacLean, lately Manager, Air Traffic Service, Sumburgh Airport (Shetland), Civil Aviation Authority.
Sources: en.wikipedia.org
===== Rail transport ===== The government intends to start a new wave of investment in the expansion of the Brazilian railway network, with the strategy being to increase investments in railway lines led by the ministry of transport; within the New PAC, the government intends to invest R$94.2 billion in 35 projects, R$55.1 billion by 2026 and more $39.1 billion in subsequent years, the majority of the investments will be through the private sector. The focus, this time, will be the passenger transport, the newspaper Poder360 found that there are 7 most advanced passenger train projects, stretches averaging 100 km connecting municipalities and metropolitan regions, among these, the longest would be the one that connects Fortaleza with Sobral, in Ceará, a stretch of more than 200 km, the others would be in the states of Maranhão, Bahia, Rio de Janeiro, Paraná, Rio Grande do Sul and the Federal District. Currently, there are only two regular passenger lines: between Vitória and Belo Horizonte, and between São Luís and Parauapebas (PA), both are also used to transport cargo; for the construction of these lines, the government sees it as essential to take advantage of the existing railway infrastructure, aimed at transporting cargo, but which is underutilized or in a precarious state of maintenance.
==== Pain circuitry ==== The outcome of NOP activation on the brain's pain circuitry is site-specific. Within the central nervous system its action can be either similar or opposite to those of opioids depending on their location. In animal models, activation of NOP in the brain stem and higher brain regions has mixed action, resulting in overall anti-opioid activity. NOP activation at the spinal cord and peripheral nervous system results in morphine-comparable analgesia in non-human primates.
== Sources == Bulletins of the Information Bureau of the People's Union for the Defense of the Motherland and Freedom Savinkov, Boris. The Fight Against the Bolsheviks // Russian Foreign Literature. Anthology in Six Volumes. Moscow: Kniga, 1990. Vol. 1, Book 2. The Union for the Defense of the Homeland and Freedom and the Yaroslavl Rebellion of 1918 // Proletarian Revolution, 1923, no. 10. Klementyev, V. F. In Bolshevik Moscow (1918–1920). Moscow: Russkiy Put, 1998. Korovin, V. V.; Rusanov, E. P. Boris Savinkov's Case // History of the Soviet Union, 1967, no. 6, pp. 143–155. Golinkov, D. L. The Collapse of the Enemy Underground. Moscow, 1971. Gopper, Karl. Four Collapses: Memoirs of General Gopper. Riga, 1920. Jekabsons, E.; Ščerbinskis, V. Participation of Latvians in White Military Forces During the Russian Civil War 1917–1920. Riga: Journal of the Latvian Institute of History, 1997. Shentalinsky, Vitaly. "His Among His Own. Savinkov in the Lubyanka." New World, no. 7 (1996).
From the first partition of Poland (1772): Polish Inflants (Latgale), the northern part of the Polotsk Voivodeship, the entire Mstsislaw Voivodeship and Vitebsk Voivodeships, and the southeastern part of the Minsk Voivodeship (about 92,000 km2) From the second partition of Poland (1793): the remaining part of the Minsk Voivodeship, the entire Kiev Voivodeship, Bracław Voivodeship and Vilnius Voivodeships, parts of Podole Voivodeship and eastern parts of the Wołyń Voivodeship and Brest Litovsk Voivodeships (about 250,000 km2) From the third partition of Poland (1795): all the territories east of the Bug River(about 120,000. km2) and after 1807 the Belostok Oblast) It consisted of 9 guberniyas: six Belarusian and Lithuanian ones that constituted the Northwestern Krai (Vilna Governorate, Kovno Governorate, Grodno Governorate, Minsk Governorate, Mogilev Governorate and Vitebsk Governorate) and three Ukrainian ones that constituted the Southwestern Krai (Volhynia Governorate, Podolia Governorate and Kiev Governorate). In the first partition, Russia gained 92,000 km2 and 1.3 million people. In the second, 250,000 km2 and 1 million people. In the third, 120,000 km2 and 1.2 million people. Overall, Russia had gained about 62 percent of the former Commonwealth territory (462,000 km2) and about 45 percent of the population (3.5 million people). The Russian partition was thus the largest and most populous of the three partitions (the other two being the Austrian Partition and the Prussian Partition).
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.